Affinage

CD7

T-cell antigen CD7 · UniProt P09564

Length
240 aa
Mass
25.4 kDa
Annotated
2026-04-28
100 papers in source corpus 24 papers cited in narrative 24 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CD7 is a type I transmembrane immunoglobulin-superfamily glycoprotein that functions as an accessory signaling receptor on T cells, NK cells, and monocytes, modulating activation, differentiation, and apoptotic susceptibility. Upon cross-linking, CD7 forms homodimers that associate with CD3 and CD45, recruit a tyrosine kinase activity, and engage PI3-kinase via a cytoplasmic YEDM motif to generate PIP3, elevate intracellular calcium, activate PKC and PTK pathways, and promote IL-2 production, IL-2Rα upregulation, integrin-mediated adhesion, and cytokine secretion (PMID:7523512, PMID:8918688, PMID:7533088, PMID:7525296). Its cognate ligand SECTM1 (K12) binds CD7 on T, NK, and monocytic cells to modulate proliferation and drive PI3K-dependent monocyte migration, while galectin-1 and galectin-3 engage CD7 to trigger mitochondrial apoptosis through cytochrome c release and caspase-3 activation (PMID:10652336, PMID:24157461, PMID:14678989, PMID:12808059). Progressive upregulation of CD7 marks lineage restriction during thymic T cell development—from multipotent CD7-negative progenitors to T/NK-committed CD7-high cells—and graded CD7 loss on peripheral CD8+ T cells delineates naive, memory, and effector subsets (PMID:17959857, PMID:12594257, PMID:8958052).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 1984 High

    Establishing CD7 as a post-translationally modified transmembrane glycoprotein resolved the basic molecular identity of this lymphocyte-surface antigen and its biosynthetic route through the secretory pathway.

    Evidence Biosynthetic labeling, tunicamycin/endo-H/endo-F glycosylation analysis, phosphoamino acid analysis in human T cells

    PMID:6609985

    Open questions at the time
    • Three-dimensional structure undetermined
    • Functional significance of serine phosphorylation and acylation unknown
  2. 1992 Medium

    Demonstrating that CD7 cross-linking delivers a co-stimulatory signal that promotes IL-2 production, IL-2Rα upregulation, calcium flux, and cytokine induction through both PKC and PTK pathways established CD7 as an activating accessory receptor on T and γδ T cells.

    Evidence Anti-CD7 mAb co-stimulation assays on PBMCs and γδ T cell lines with PKC/PTK inhibitor dissection, calcium flux, and cytokine measurement

    PMID:1372842 PMID:1709867 PMID:2459196

    Open questions at the time
    • Proximal signaling complex not yet identified
    • Basis for differential activation of γδ versus αβ T cells unclear
  3. 1994 High

    Identifying CD7 as a homodimer physically associated with CD3 and CD45 that co-precipitates tyrosine kinase activity, and showing that CD7 cross-linking drives integrin-mediated adhesion and NK cell activation, defined the signaling complex and broadened CD7 function beyond T cell co-stimulation.

    Evidence Co-IP, FRET, in vitro kinase assays on T cells; anti-CD7 cross-linking on NK cells with calcium flux, activation marker upregulation, cytotoxicity and adhesion assays

    PMID:7506726 PMID:7523512 PMID:7525296

    Open questions at the time
    • Identity of the 80 kDa kinase substrate unknown
    • Specific tyrosine kinase(s) in the CD7 complex not identified
  4. 1996 High

    Mapping the PI3K recruitment site to the cytoplasmic YEDM motif of CD7 and showing that cross-linking triggers PIP3 generation provided the first direct biochemical mechanism linking CD7 engagement to lipid second-messenger signaling.

    Evidence Co-precipitation with anti-CD7, GST-p85 SH2 pulldown, peptide competition, PI3K enzymatic activity assay, D-3 phosphoinositide lipid analysis

    PMID:7533088 PMID:8918688

    Open questions at the time
    • Downstream effectors of PIP3 in CD7 signaling (e.g., Akt activation) not directly demonstrated
    • Relative contribution of PI3K vs PKC/PTK arms to functional outcomes undefined
  5. 1997 High

    CD7-knockout mice revealed that CD7 is dispensable for steady-state lymphoid development but contributes to thymocyte homeostasis and antigen-specific CTL function, separating developmental from effector roles.

    Evidence Two independent targeted gene disruptions in mice; thymocyte enumeration, mitogenic responses, NK cytotoxicity, and MHC class I-restricted CTL assays

    PMID:9466315 PMID:9637484

    Open questions at the time
    • Redundancy with other co-stimulatory receptors not dissected
    • Mechanism of reduced CTL activity not resolved
  6. 1999 High

    The finding that CD7-deficient mice resist LPS-induced shock and have reduced hepatic NKT cells linked CD7 to innate inflammatory responses and NKT cell homeostasis in vivo.

    Evidence CD7 KO mice challenged with LPS/D-galactosamine; survival, serum cytokine ELISA, liver mononuclear cell phenotyping

    PMID:10075985

    Open questions at the time
    • Whether CD7 directly regulates NKT cell development or survival is unclear
    • Cell-intrinsic vs cell-extrinsic mechanism not distinguished
  7. 2000 High

    Identification of SECTM1 (K12) as the cognate ligand of CD7 that activates NK cells and inhibits ConA-driven T cell proliferation resolved a long-standing search for CD7's natural binding partner.

    Evidence K12-Fc fusion binding, immunoprecipitation of ~40 kDa protein from NK cells, cDNA expression library screening, functional NK activation and T cell inhibition assays

    PMID:10652336

    Open questions at the time
    • Structural basis of SECTM1–CD7 interaction undetermined
    • Whether SECTM1 is the sole physiological ligand unknown
  8. 2003 High

    Demonstrating that galectin-1 and galectin-3 bind CD7 to trigger mitochondrial apoptosis (cytochrome c release, caspase-3 activation) established CD7 as a death receptor for galectin family members, with glycosylation state as a susceptibility determinant.

    Evidence Galectin-3 receptor identification, lactose inhibition, caspase/cytochrome c assays; galectin-1 apoptosis on Sézary T cells with glycosylation analysis

    PMID:12808059 PMID:14678989

    Open questions at the time
    • Mechanism coupling galectin–CD7 binding to mitochondrial pathway not elucidated
    • Whether the YEDM/PI3K signaling axis is involved in galectin-induced death unknown
  9. 2007 High

    Correlating graded CD7 expression with progressive lineage restriction in thymic progenitors and with effector differentiation in peripheral CD8+ T cells established CD7 level as a functional marker of T cell commitment and differentiation state.

    Evidence Sorted CD7-neg/int/high CD34+ thymocytes in multi-lineage differentiation assays; sorted CD7hi/lo/neg CD8+ T cell functional analysis; serial stimulation and re-culture of CD4+ T cells

    PMID:12594257 PMID:17959857 PMID:8958052

    Open questions at the time
    • Transcription factors upstream of CD7 regulation during lineage commitment largely undefined beyond Twist2
    • Whether CD7 signaling actively drives commitment or is merely a marker unclear
  10. 2013 Medium

    Extending CD7 function to monocytes by showing that tumor-derived SECTM1 promotes PI3K-dependent monocyte migration via CD7 broadened the receptor's role to myeloid innate immunity and tumor microenvironment biology.

    Evidence SECTM1–CD7 binding on monocytes, transwell migration assay with PI3K pathway analysis, flow cytometry during M-CSF differentiation

    PMID:24157461

    Open questions at the time
    • In vivo relevance of CD7-dependent monocyte migration not tested
    • Other signaling intermediates downstream of PI3K in monocytes not identified
  11. 2017 High

    CRISPR/Cas9 disruption of CD7 in CAR T cells eliminated fratricide and enabled effective anti-CD7 CAR T therapy against T-ALL in xenograft models, validating CD7 as both a therapeutic target and an expendable molecule in engineered T cells.

    Evidence CRISPR/Cas9 CD7 KO, CAR T expansion/fratricide assays, cytotoxicity against T-ALL lines and primary tumors, xenograft model

    PMID:28539325

    Open questions at the time
    • Long-term consequences of CD7 loss on engineered T cell fitness in patients unknown
    • Whether CD7 loss alters galectin-mediated apoptotic regulation of CAR T cells untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key open questions include the structural basis of CD7–SECTM1 and CD7–galectin interactions, the identity of the tyrosine kinase(s) directly recruited to the CD7–CD3–CD45 complex, the signaling mechanism linking CD7-galectin binding to mitochondrial apoptosis, and whether CD7 actively instructs lineage commitment or passively marks it.
  • No crystal or cryo-EM structure for CD7 or its ligand complexes
  • Specific kinase(s) in the CD7 complex remain unidentified
  • Active vs passive role of CD7 in thymic lineage commitment unresolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060089 molecular transducer activity 5 GO:0060090 molecular adaptor activity 2
Localization
GO:0005886 plasma membrane 5
Pathway
R-HSA-168256 Immune System 6 R-HSA-5357801 Programmed Cell Death 2
Partners
CD3EITGB1LGALS1LGALS3PIK3R1PTPRCSECTM1
Complex memberships
CD7–CD3–CD45 complex

Evidence

Reading pass · 24 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1984 CD7 (gp40) is a monomeric transmembrane glycoprotein of Mr=40,000 that is asymmetrically inserted into the rough endoplasmic reticulum as a transmembrane structure, undergoes N-linked glycosylation (two high-mannose type glycans processed to complex oligosaccharides during transport), also contains O-linked glycans, covalently associated fatty acid, and is phosphorylated on phosphoserine. Biosynthetic labeling, tunicamycin inhibition, endo-F/endo-H cleavage, gal-NAc oligosaccharidase digestion, 32P phosphate labeling, phosphoamino acid analysis Journal of immunology High 6609985
1988 Immobilized anti-CD7 monoclonal antibody delivers a co-mitogenic signal to T cells in conjunction with suboptimal anti-CD3 stimulation, promoting IL-2 production and IL-2 receptor expression; this co-mitogenic effect can be replicated by PMA but not by calcium ionophore. Co-mitogenic proliferation assay with solid-phase antibodies, IL-2 and IL-2R measurement, PKC/PTK pharmacological dissection Journal of immunology Medium 2459196
1991 CD7 cross-linking on TCRγ/δ+ T cell lines causes rapid cytoplasmic free calcium elevation, IL-2 production, and induction of TNF-α, TNF-β, and GM-CSF mRNAs, directly activating these cells; the same anti-CD7 antibody fails to activate TCRα/β+ T cells. Calcium flux measurement, cytokine ELISA, mRNA induction assay, proliferation assay with anti-CD7 mAb stimulation European journal of immunology Medium 1709867
1991 CD7 gene transcription is selectively induced by calcium flux (ionomycin) in a cyclosporin A-sensitive, extracellular calcium-dependent, tyrosine-kinase-independent manner; transcriptional induction peaks at 1 hour and precedes surface upregulation. Ionomycin stimulation, CD7 mRNA half-life measurement, transcriptional run-on analysis, pharmacological inhibitors, flow cytometry Journal of immunology High 1717576
1992 CD7 augments T cell proliferation via the IL-2 autocrine pathway by increasing IL-2 production and IL-2Rα (CD25) expression through both PKC and PTK signaling pathways; inhibitors H-7 (PKC) and genistein (PTK) suppress CD7-mediated co-mitogenesis. PBMC proliferation assays, IL-2 measurement, IL-2Rα expression analysis, PKC/PTK inhibitor treatment Cellular immunology Medium 1372842
1994 CD7 cross-linking on NK cells induces rapid cytoplasmic calcium elevation, upregulation of CD25, CD71, HLA-DR, CD69, and CD54, IFN-γ secretion, NK cell proliferation, enhanced cytotoxicity against K562 targets, and augmented adhesion to fibronectin; however CD7 does not transduce a direct lytic signal. Anti-CD7 mAb cross-linking, calcium flux, flow cytometry, thymidine incorporation, cytotoxicity assay, fibronectin adhesion assay Journal of immunology High 7506726
1994 CD7 exists in an oligomeric complex (homodimer) physically associated with CD3 and CD45 on human T cells; this complex contains a tyrosine kinase whose major substrate is CD45. Co-immunoprecipitation, Western blotting, fluorescence resonance energy transfer (FRET), in vitro phosphorylation assay Journal of immunology High 7523512
1994 CD7 cross-linking mediates rapid tyrosine phosphorylation and upregulates β1 and β2 integrin-mediated T cell adhesion; this effect is completely blocked by the tyrosine kinase inhibitor herbimycin A, and CD7 immunoprecipitates contain in vitro kinase activity phosphorylating an 80 kDa substrate on tyrosine, serine, and threonine residues. Anti-CD7 antibody cross-linking, adhesion assay, herbimycin A inhibition, anti-phosphotyrosine immunoblotting, in vitro kinase assay, phosphoamino acid analysis European journal of immunology High 7525296
1995 CD7 cross-linking leads to association with phosphoinositide 3-kinase (PI3K) and production of D-3 phosphoinositides including phosphatidylinositol 3,4,5-trisphosphate (PIP3); this is accompanied by phosphatidic acid formation in the absence of phosphatidylinositol-4,5-bisphosphate metabolism. Co-precipitation of CD7 with PI3K, phosphoinositide lipid analysis, comparison with CD3 and CD28 stimulation European journal of immunology High 7533088
1996 The cytoplasmic tail of CD7 interacts with the p85 adaptor subunit of PI3-kinase via a pTyr-X-X-Met (YEDM) motif; CD7 cross-linking markedly increases the amount of PI3-kinase activity associated with CD7. Co-precipitation with anti-CD7 mAb, recombinant p85 SH2-GST fusion protein pulldown, peptide competition, PI3-kinase activity assay International immunology High 8918688
1997 CD7-deficient mice show normal lymphocyte development but have transient increases in thymocyte numbers at 3 months of age and reduced antigen-specific MHC class I-restricted CTL activity, demonstrating a role for CD7 in regulating intrathymic T cell development and CTL effector function. Targeted gene disruption (CD7 knockout mice), thymocyte enumeration at multiple timepoints, antigen-specific CTL assay Journal of immunology High 9637484
1997 Targeted disruption of murine CD7 results in mice with normal lymphocyte populations, normal serum Ig levels, normal mitogenic responses, and normal NK cytotoxicity, indicating CD7 is dispensable for normal lymphoid development under steady-state conditions. Targeted gene disruption, lymphocyte subset analysis, mitogen proliferation assays, NK cytotoxicity assay International immunology High 9466315
1999 CD7-deficient mice are resistant to LPS-induced shock; they show decreased serum IFN-γ and TNF-α levels after LPS/D-galactosamine challenge, and have reduced numbers of liver NK1.1+/CD3+ NKT cells, establishing CD7 as a key molecule in the inflammatory response leading to LPS-induced shock through regulation of NKT cell numbers and cytokine production. CD7 knockout mice, LPS/D-gal challenge survival assay, cytokine ELISA, liver mRNA analysis, liver mononuclear cell phenotyping by flow cytometry Journal of experimental medicine High 10075985
2000 K12 (SECTM1) is identified as a cognate ligand of CD7; K12-Fc fusion protein binds specifically to T and NK cells and precipitates an ~40 kDa protein from NK cell lysates identified as CD7. Mouse K12 inhibits ConA-induced but not anti-TCR-induced T cell proliferation, and human K12-Fc stimulates upregulation of CD25, CD54, and CD69 on human NK cells. K12-Fc fusion protein flow cytometry binding, immunoprecipitation from 35S-radiolabeled NK cells, cDNA expression library screening, NK cell activation assay, T cell proliferation inhibition assay Journal of biological chemistry High 10652336
2003 Galectin-3 binds CD7 and CD29 (β1 integrin) on the T cell surface and induces type II (mitochondrial) apoptosis including cytochrome c release and caspase-3 activation but not caspase-8 activation; this occurs through carbohydrate-dependent interactions. Identification of Gal-3 cell surface receptors, lactose inhibition assay, caspase activity measurement, cytochrome c release assay, Gal-3 transfection Cancer research High 14678989
2003 CD7 expression is necessary but not sufficient for galectin-1-induced apoptosis of Sezary T cells; cell surface glycosylation (sialylated core 1 O-glycans) additionally determines susceptibility, as CD7-positive Sezary cells with this glycotype resist galectin-1-mediated death. Galectin-1 apoptosis assay, CD7 expression analysis, cell surface glycosylation analysis of Sezary cell lines and primary lesions, in vivo galectin-1 detection by IHC Modern pathology Medium 12808059
2003 CD7 expression on CD8+ T cells marks distinct differentiation subsets with different functional properties: CD7-high cells contain naive and memory cells; CD7-low and CD7-negative cells contain effector cells that can be further divided into cytokine-secreting and lytic effector subsets. Multi-parameter flow cytometry, functional cytokine secretion assays, cytotoxicity assays on sorted CD7hi/lo/neg CD8+ T cell subsets Journal of immunology Medium 12594257
2007 Progressive restriction in lymphoid/myeloid lineage potential in human thymic progenitors correlates with increasing CD7 expression: CD7-negative CD34+ thymocytes retain full lympho-myeloid potential and express HSC genes; CD7-intermediate cells produce B, T, and NK cells; CD7-high cells produce only T and NK cells. Fluorescence-activated cell sorting by CD7 expression level, multi-lineage in vitro differentiation assays (B, T, NK, myelo-erythroid), gene expression analysis Blood High 17959857
2009 CD7 co-expression with CD56 distinguishes functional NK cells from CD56+ monocyte/DC-like cells; only CD7+CD56+ NK cells secrete IFN-γ and degranulate after IL-12/IL-18 or K562 stimulation, while CD7-negative CD56+ myeloid cells stimulate allogeneic responses but lack NK effector functions. Multi-color flow cytometry, IFN-γ secretion assay, degranulation (CD107a) assay, allogeneic stimulation assay, K562 cytotoxicity assay Blood High 19805616
2009 Twist2 transcription factor downregulates CD7 gene promoter activity in T cells through its C-terminal domain and possibly via histone deacetylation; ectopic Twist2 expression reduces CD7 surface levels and decreases galectin-1-induced apoptosis. Twist2 ectopic expression, CD7 promoter activity assay, C-terminal deletion mutant analysis, HDAC inhibitor treatment (TSA, sodium butyrate), galectin-1 apoptosis assay Molecules and cells Medium 19937140
2013 SECTM1 (K12) produced by tumor cells binds CD7 on monocytes and significantly increases monocyte migration via activation of the PI3K pathway; CD7 is expressed on human monocytes and macrophages and its expression decreases upon M-CSF-induced differentiation. SECTM1-CD7 binding assay, monocyte migration assay, PI3K pathway analysis, flow cytometry for CD7 expression on monocytes/macrophages, conditioned medium experiments Journal of investigative dermatology Medium 24157461
2017 Targeted genomic disruption of the CD7 gene in T cells prevents fratricide when a CD7-specific CAR is expressed; CD7-edited CAR T cells expand normally, retain cytotoxic function against malignant T-cell lines and primary tumors, and are protective in a mouse xenograft model of T-ALL. CRISPR/Cas9 gene editing, CAR T cell expansion and fratricide assays, cytotoxicity assays, xenograft mouse model Blood High 28539325
2022 Naturally selected CD7-CAR T cells overcome fratricide because the CD7-targeting CAR masks or sequesters CD7 molecules on the T cell surface, minimizing accessible CD7 epitopes without requiring genetic knockout; this approach yields a higher proportion of central memory CD8+ T cells compared to sorted CD7-negative or CD7-knocked-out CAR T cells. Flow cytometry of CD7 surface expression, comparison of CD7-masked vs CD7-KO vs CD7-negative CAR T cell products, central memory phenotype analysis Blood Medium 35500125
1996 CD7 expression is transcriptionally regulated and absent CD7 expression in a subset of CD4+ memory T cells represents a stable, separate differentiation state: once naive T cells differentiate into CD7-negative memory cells through repeated stimulation, sorted CD7-negative cells do not re-express CD7 and show no CD7 mRNA. Serial stimulation of sorted naive CD4+ T cells, RT-PCR for CD7 mRNA, cell sorting and re-culture of CD7+ and CD7- populations, surface phenotyping Immunology Medium 8958052

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2017 CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 378 28539325
2003 CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer research 303 14678989
2021 Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 240 34324392
2003 NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. The Journal of experimental medicine 206 12756263
1997 CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood 174 9310493
2022 Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell research 163 36151216
2022 Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood 153 35500125
2002 MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nature immunology 152 12021778
1988 Triggering of co-mitogenic signals in T cell proliferation by anti-LFA-1 (CD18, CD11a), LFA-3, and CD7 monoclonal antibodies. Journal of immunology (Baltimore, Md. : 1950) 143 2459196
2000 Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15. Infection and immunity 139 10858228
1993 Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. Blood 135 7683218
1989 CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity. British journal of haematology 120 2482063
1986 3A1 (CD7) expression precedes T beta gene rearrangements in precursor T (lymphoblastic) neoplasms. Blood 120 3013340
1994 Expression and function of CD7 molecule on human natural killer cells. Journal of immunology (Baltimore, Md. : 1950) 114 7506726
1988 The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. Journal of immunology (Baltimore, Md. : 1950) 101 3257508
2024 Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis. The New England journal of medicine 93 38657244
2022 Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 87 35435984
2009 Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4. Blood 86 19805616
1984 Isolation and characterization of a human T lymphocyte-associated glycoprotein (gp40). Journal of immunology (Baltimore, Md. : 1950) 81 6609985
2007 Human intrathymic lineage commitment is marked by differential CD7 expression: identification of CD7- lympho-myeloid thymic progenitors. Blood 79 17959857
1997 Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leukemia & lymphoma 77 9322891
1993 Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood 73 7694687
2022 T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal transduction and targeted therapy 72 35332132
2003 CD7 is a differentiation marker that identifies multiple CD8 T cell effector subsets. Journal of immunology (Baltimore, Md. : 1950) 71 12594257
2000 The luminal part of the murine cytomegalovirus glycoprotein gp40 catalyzes the retention of MHC class I molecules. The EMBO journal 71 10698929
2023 Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. Journal of hematology & oncology 68 37020231
2005 Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer research 68 15833872
2023 Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood cancer journal 65 37095094
1989 Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma. Blood 62 2473811
1999 Structure and function of the CD7 molecule. Critical reviews in immunology 61 10530432
2017 Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. International journal of nanomedicine 59 28331319
1996 Expression of gp40, the murine homologue of human epithelial cell adhesion molecule (Ep-CAM), by murine dendritic cells. European journal of immunology 56 8566052
1995 Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 56 9815887
2024 Fratricide-resistant CD7-CAR T cells in T-ALL. Nature medicine 55 39227445
2001 T cell signal transduction and the role of CD7 in costimulation. Immunologic research 55 11485208
2022 Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood 54 35914226
2001 CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome. Journal of the American Academy of Dermatology 53 11209115
1998 Immunologic characterization of CD7-deficient mice. Journal of immunology (Baltimore, Md. : 1950) 53 9637484
2007 Cryptosporidium parvum glycoprotein gp40 localizes to the sporozoite surface by association with gp15. Molecular and biochemical parasitology 52 17719100
2002 Low CD7 expression in benign and malignant cutaneous lymphocytic infiltrates: experience with an antibody reactive with paraffin-embedded tissue. The American Journal of dermatopathology 48 11803274
1998 Biologic and clinical significance of CD7 expression in acute myeloid leukemia. American journal of hematology 47 9692390
1993 Phenotypic characterization of CD7+, CD3+, and CD8+ lymphocytes from first trimester human decidua using two-color flow cytometry. American journal of reproductive immunology (New York, N.Y. : 1989) 47 7684920
1989 Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions. Journal of immunology (Baltimore, Md. : 1950) 47 2479683
1994 CD7 is associated with CD3 and CD45 on human T cells. Journal of immunology (Baltimore, Md. : 1950) 46 7523512
2006 Proteolytic processing of the Cryptosporidium glycoprotein gp40/15 by human furin and by a parasite-derived furin-like protease activity. Infection and immunity 45 17043102
1992 CD7 augments T cell proliferation via the interleukin-2 autocrine pathway. Cellular immunology 45 1372842
2023 Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy. American journal of hematology 43 37740926
1996 CD7-negative T cells represent a separate differentiation pathway in a subset of post-thymic helper T cells. Immunology 42 8958052
1991 Direct involvement of CD7 (gp40) in activation of TcR gamma/delta+ T cells. European journal of immunology 42 1709867
2016 Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells. Oncotarget 40 27083001
2003 Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 40 12808059
2001 Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sézary syndrome). The Journal of investigative dermatology 40 11564173
2000 Identification of CD7 as a cognate of the human K12 (SECTM1) protein. The Journal of biological chemistry 38 10652336
1997 In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clinical cancer research : an official journal of the American Association for Cancer Research 38 9815763
1997 Molecular characterization of gp40, a mucin-type glycoprotein from the apical plasma membrane of Madin-Darby canine kidney cells (type I). The Biochemical journal 37 9337856
1997 Targeted gene disruption of murine CD7. International immunology 37 9466315
1987 Use of the monoclonal antibody WR17, identifying the CD37 gp40-45 Kd antigen complex, in the diagnosis of B-lymphoid malignancy. The Journal of pathology 36 3305845
2001 Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin. British journal of cancer 35 11207056
2021 CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy. JCI insight 34 34423790
2009 Overexpression of CD7 in classical Hodgkin lymphoma-infiltrating T lymphocytes. Cytometry. Part B, Clinical cytometry 32 18956470
1995 Signal transduction by a CD16/CD7/Jak2 fusion protein. The Journal of biological chemistry 32 7543102
1989 Antigenic modulation induced by four monoclonal antibodies adsorbed on gold particles (specificity anti-CD4, anti-CD5, anti-CD7, and anti-150-kDa antigen): relationship between modulation and cytotoxic activity of immunotoxins. Experimental cell research 32 2785456
2005 Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Experimental and molecular pathology 31 16005710
2018 T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. Theranostics 30 30613283
1996 Biological characteristics of CD7(+) acute leukemia. Leukemia & lymphoma 30 8726405
2025 Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia. Blood 29 39561281
2022 CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia. Experimental hematology & oncology 29 36175988
2008 Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. American journal of clinical pathology 29 18343790
1995 Antibody ligation of CD7 leads to association with phosphoinositide 3-kinase and phosphatidylinositol 3,4,5-trisphosphate formation in T lymphocytes. European journal of immunology 29 7533088
2013 SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway. The Journal of investigative dermatology 27 24157461
2012 Structural basis of mouse cytomegalovirus m152/gp40 interaction with RAE1γ reveals a paradigm for MHC/MHC interaction in immune evasion. Proceedings of the National Academy of Sciences of the United States of America 27 23169621
2011 Serum IgG response to Cryptosporidium immunodominant antigen gp15 and polymorphic antigen gp40 in children with cryptosporidiosis in South India. Clinical and vaccine immunology : CVI 26 21288997
2010 Direct interaction of the mouse cytomegalovirus m152/gp40 immunoevasin with RAE-1 isoforms. Biochemistry 26 20166740
1994 Tyrosine kinase activity associated with the CD7 antigen: correlation with regulation of T cell integrin function. European journal of immunology 26 7525296
2022 Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma. Biomarker research 25 35130959
1999 Resistance of CD7-deficient mice to lipopolysaccharide-induced shock syndromes. The Journal of experimental medicine 25 10075985
1997 Construction and characterization of human CD7-specific single-chain Fv immunotoxins. Journal of immunology (Baltimore, Md. : 1950) 25 9120282
1996 Functional association of CD7 with phosphatidylinositol 3-kinase: interaction via a YEDM motif. International immunology 25 8918688
1991 Induction of T cell CD7 gene transcription by nonmitogenic ionomycin-induced transmembrane calcium flux. Journal of immunology (Baltimore, Md. : 1950) 25 1717576
2023 Single-Cell Transcriptomics Reveals Immune Reconstitution in Patients with R/R T-ALL/LBL Treated with Donor-Derived CD7 CAR-T Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 24 36735547
2023 Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and lymphoma and acute myeloid leukemia: recent advances. Frontiers in immunology 24 37215124
2002 C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread. Journal of virology 24 12186891
2022 Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody. Molecular therapy oncolytics 22 35317521
2011 Autoimmune enteropathy with a CD8+ CD7- T-cell small bowel intraepithelial lymphocytosis: case report and literature review. BMC gastroenterology 22 22126605
2000 CD7 expression distinguishes subsets of CD4(+) T cells with distinct functional properties and ability to support replication of HIV-1. European journal of immunology 22 10671214
1998 CD7 positive hematopoietic progenitors and acute myeloid leukemia and other minimally differentiated leukemia. Leukemia & lymphoma 22 9720718
1992 Biological characteristics of CD7 positive acute myelogenous leukaemia. British journal of haematology 22 1283077
1991 CD4 and CD7 molecules as targets for drug delivery from antibody bearing liposomes. Experimental cell research 22 1704842
2009 Twist2 regulates CD7 expression and galectin-1-induced apoptosis in mature T-cells. Molecules and cells 21 19937140
2004 The importance of CD7 and CD56 antigens in acute leukaemias. International journal of clinical practice 21 15055863
2023 Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection. Leukemia 20 37391486
2007 Stable expression of Cryptosporidium parvum glycoprotein gp40/15 in Toxoplasma gondii. Molecular and biochemical parasitology 20 17275106
2005 Expression of the CD7 ligand K-12 in human thymic epithelial cells: regulation by IFN-gamma. Journal of clinical immunology 19 15742156
2021 Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia. International immunopharmacology 18 33965880
2008 Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes. Leukemia research 18 18718658
2003 CD7 expression in reactive and malignant human skin T-lymphocytes. Anticancer research 18 12894562
2022 Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML). Journal of translational medicine 17 36517851
1993 Isolation and characterization of mouse CD7 cDNA. Immunogenetics 17 7678579
2006 Evaluation of CD7 and terminal deoxynucleotidyl transferase (TdT) expression in CD34+ myeloblasts from patients with myelodysplastic syndrome. Leukemia research 16 16417922
1994 Clinical and biologic characteristics of CD7+ acute myeloid leukemia. Our experience and literature review. Cancer genetics and cytogenetics 15 7513604